Unknown

Dataset Information

0

Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety.

ABSTRACT: In this paper, a series of peptidomimetic SARS-CoV-2 3CL protease inhibitors with new P2 and P4 positions were synthesized and evaluated. Among these compounds, 1a and 2b exhibited obvious 3CLpro inhibitory activities with IC50 of 18.06 nM and 22.42 nM, respectively. 1a and 2b also showed excellent antiviral activities against SARS-CoV-2 in vitro with EC50 of 313.0 nM and 170.2 nM, respectively, the antiviral activities of 1a and 2b were 2- and 4-fold better than that of nirmatrelvir, respectively. In vitro studies revealed that these two compounds had no significant cytotoxicity. Further metabolic stability tests and pharmacokinetic studies showed that the metabolic stability of 1a and 2b in liver microsomes was significantly improved, and 2b had similar pharmacokinetic parameters to that of nirmatrelvir in mice.

SUBMITTER: Zhu M 

PROVIDER: S-EPMC10166615 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety.

Zhu Mengwei M   Fu Tiantian T   You Mengyuan M   Cao Junyuan J   Yang Hanxi H   Chen Xinyao X   Zhang Qiumeng Q   Xu Yechun Y   Jiang Xiangrui X   Zhang Leike L   Su Haixia H   Zhang Yan Y   Shen Jingshan J  

Bioorganic & medicinal chemistry 20230508

In this paper, a series of peptidomimetic SARS-CoV-2 3CL protease inhibitors with new P2 and P4 positions were synthesized and evaluated. Among these compounds, 1a and 2b exhibited obvious 3CL<sup>pro</sup> inhibitory activities with IC<sub>50</sub> of 18.06 nM and 22.42 nM, respectively. 1a and 2b also showed excellent antiviral activities against SARS-CoV-2 in vitro with EC<sub>50</sub> of 313.0 nM and 170.2 nM, respectively, the antiviral activities of 1a and 2b were 2- and 4-fold better than  ...[more]

Similar Datasets

Unknown Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.
| S-EPMC8529539 | biostudies-literature
Unknown Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety.
| S-EPMC7127713 | biostudies-literature
Unknown Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CL<sup>pro</sup> inhibitors against SARS-CoV-2.
| S-EPMC10204345 | biostudies-literature
Unknown Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease.
| S-EPMC8206078 | biostudies-literature
Unknown Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.
| S-EPMC5891363 | biostudies-literature
Unknown 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
| S-EPMC8340582 | biostudies-literature
Unknown Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.
| S-EPMC7115367 | biostudies-literature
Unknown Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors.
| S-EPMC2112940 | biostudies-other
Unknown Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen.
| S-EPMC9528019 | biostudies-literature
Unknown Design, synthesis and biological activities of echinopsine derivatives containing acylhydrazone moiety.
| S-EPMC8861054 | biostudies-literature